Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Menlo, Cutia enter license agreement for AMZEEQ, minocycline products » 08:19
04/23/20
04/23
08:19
04/23/20
08:19
MNLO

Menlo Therapeutics

$1.31 /

+0.02 (+1.55%)

, FOMX

Foamix

$0.00 /

+ (+0.00%)

Menlo Therapeutics Inc.…

Menlo Therapeutics Inc. (MNLO) announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. (FOMX), has entered into a licensing agreement with specialty pharmaceutical company Cutia Therapeutics Limited, an affiliate of Cutia Therapeutics for AMZEEQ topical foam, 4% as well as its other topical minocycline product candidates, once approved, on an exclusive basis in Greater China. Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ and, if approved in the U.S., FMX103 and FCD105 in the Greater China territory. Foamix will supply the finished licensed products to Cutia for clinical and commercial use. Foamix will receive an upfront cash payment of $10 million and will be eligible to receive an additional $1 million payment upon the receipt of marketing approval in China of the first licensed product. Foamix will also receive royalties on net sales of any licensed products. In October 2019, Foamix received U.S. Food and Drug Administration approval for AMZEEQ, a minocycline topical foam, 4%, for the treatment of non-nodular inflammatory moderate-to-severe acne vulgaris in adults and pediatric patients 9 years of age and older. In addition to AMZEEQ, the Company is working to develop and commercialize in the U.S. a topical minocycline foam, 1.5% for the potential treatment of inflammatory lesions (papules and pustules) of rosacea in adults, which is currently being reviewed by the FDA with a PDUFA action date of June 2, 2020, and FCD105, a topical foam combination of minocycline and adapalene therapy for the potential treatment of acne vulgaris, which is currently in Phase 2 clinical development with top line results expected in the second quarter of 2020.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$1.31 /

+0.02 (+1.55%)

04/07/20 Barclays
Menlo Therapeutics price target lowered to $2 from $8 at Barclays
04/07/20 H.C. Wainwright
Menlo Therapeutics price target lowered to $2 from $8 at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Barclays
Menlo Therapeutics initiated with an Overweight at Barclays
FOMX Foamix
$0.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
Over a quarter ago
Hot Stocks
Menlo Therapeutics says LEO Pharma remedies Finacea Foam supply chain issues » 08:08
04/02/20
04/02
08:08
04/02/20
08:08
MNLO

Menlo Therapeutics

$2.39 /

-0.27 (-10.15%)

, FOMX

Foamix

$0.00 /

+ (+0.00%)

The company said,…

The company said, "Menlo (MNLO) further announces that LEO Pharma has remedied the supply chain issues related to Finacea Foam (FOMX) that Foamix previously disclosed in April 2019. Pursuant to the license agreement between Foamix and LEO Pharma, Foamix is entitled to the payment of royalties based on the net sales of Finacea Foam. This week, LEO Pharma informed Menlo that it has remedied its supply issues and expects to resupply batches of Finacea Foam for commercial sales in the U.S. in the coming weeks. Following the resupply, we anticipate that our royalty payments for Finacea Foam will increase."

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.39 /

-0.27 (-10.15%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Barclays
Menlo Therapeutics initiated with an Overweight at Barclays
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
FOMX Foamix
$0.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
Hot Stocks
Menlo Therapeutics announces settlement to conclude Finacea Foam litigation » 08:07
04/02/20
04/02
08:07
04/02/20
08:07
MNLO

Menlo Therapeutics

$2.39 /

-0.27 (-10.15%)

, FOMX

Foamix

$0.00 /

+ (+0.00%)

, TEVA

Teva

$8.47 /

-0.51 (-5.68%)

, PRGO

Perrigo

$45.00 /

-3.13 (-6.50%)

Menlo Therapeutics (MNLO)…

Menlo Therapeutics (MNLO) announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. (FOMX) has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea Foam. Details of the settlement agreement are confidential, and the settlement agreement is subject to the review of the Federal Trade Commission and the U.S. Department of Justice. Foamix is the owner of patents that have been licensed to LEO Pharma A/S to market Finacea Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea. This settlement concludes the litigation relating to Finacea Foam and comes after the settlements in October 2019 with an affiliate of Teva Pharmaceutical Industries (TEVA) and in April 2019 with affiliates of Perrigo Company (PRGO).

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.39 /

-0.27 (-10.15%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Barclays
Menlo Therapeutics initiated with an Overweight at Barclays
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
FOMX Foamix
$0.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
TEVA Teva
$8.47 /

-0.51 (-5.68%)

03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
03/09/20 Oppenheimer
Amgen price target lowered to $250 from $256 at Oppenheimer
02/26/20 H.C. Wainwright
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results
02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
PRGO Perrigo
$45.00 /

-3.13 (-6.50%)

03/24/20 JPMorgan
JPMorgan upgrades 'highly defensive' Perrigo to Overweight from Neutral
03/24/20 JPMorgan
Perrigo upgraded to Overweight from Neutral at JPMorgan
03/20/20 SVB Leerink
Perrigo well positioned in strong flu season backdrop, says SVB Leerink
03/20/20 SVB Leerink
Perrigo upgraded to Outperform from Market Perform at SVB Leerink
Conference/Events
Menlo Therapeutics to hold a conference call » 08:25
03/12/20
03/12
08:25
03/12/20
08:25
FOMX

Foamix

$3.00 /

+ (+0.00%)

, MNLO

Menlo Therapeutics

$3.30 /

-0.455 (-12.12%)

Conference call to…

Conference call to discuss the merger with Foamix and provide a corporate update will be held on March 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
FOMX Foamix
$3.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
MNLO Menlo Therapeutics
$3.30 /

-0.455 (-12.12%)

03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
Hot Stocks
Menlo Therapeutics expects data from Foamix Phase 2 trial for FCD105 in 2Q20  07:50
03/12/20
03/12
07:50
03/12/20
07:50
MNLO

Menlo Therapeutics

$3.30 /

-0.455 (-12.12%)

, FOMX

Foamix

$3.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
MNLO Menlo Therapeutics
$3.30 /

-0.455 (-12.12%)

03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
FOMX Foamix
$3.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
Earnings
Menlo Therapeutics reports Foamix FY19 EPS ($1.66) vs. ($1.70) last year » 07:49
03/12/20
03/12
07:49
03/12/20
07:49
MNLO

Menlo Therapeutics

$3.30 /

-0.455 (-12.12%)

, FOMX

Foamix

$3.00 /

+ (+0.00%)

Reports 2019 revenue…

Reports 2019 revenue $443,000 vs. $3.6M last year.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$3.30 /

-0.455 (-12.12%)

03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
FOMX Foamix
$3.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
Conference/Events
Menlo Therapeutics to hold a conference call » 04:55
03/12/20
03/12
04:55
03/12/20
04:55
FOMX

Foamix

$3.00 /

+ (+0.00%)

, MNLO

Menlo Therapeutics

$3.30 /

-0.455 (-12.12%)

Conference call to…

Conference call to discuss the merger with Foamix and provide a corporate update will be held on March 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
FOMX Foamix
$3.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
MNLO Menlo Therapeutics
$3.30 /

-0.455 (-12.12%)

03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
03/11/20 BofA
Menlo Therapeutics initiated with a Buy at BofA
10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
Options
One new option listing and two option delistings on March 10th » 08:30
03/10/20
03/10
08:30
03/10/20
08:30
MNLO

Menlo Therapeutics

$3.54 /

-0.62 (-14.90%)

, FOMX

Foamix

$3.00 /

+ (+0.00%)

, ZAYO

Zayo Group

$34.99 /

+ (+0.00%)

New option listings for…

New option listings for March 10th include Menlo Therapeutics Inc (MNLO). Option delistings effective March 10th include Foamix Pharmaceuticals Ltd (FOMX) and Zayo Group Holdings Inc (ZAYO).

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$3.54 /

-0.62 (-14.90%)

10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
FOMX Foamix
$3.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
ZAYO Zayo Group
$34.99 /

+ (+0.00%)

05/22/19
Fly Intel: Top five analyst downgrades
05/22/19 Raymond James
Zayo Group downgraded to Market Perform from Outperform at Raymond James
05/20/19 SunTrust
Zayo Group downgraded to Hold from Buy at SunTrust
05/20/19 SunTrust
Zayo Group downgraded to Hold from Buy at SunTrust
Conference/Events
Menlo Therapeutics to hold a conference call » 17:04
03/09/20
03/09
17:04
03/09/20
17:04
FOMX

Foamix

$3.00 /

+ (+0.00%)

, MNLO

Menlo Therapeutics

$3.54 /

-0.62 (-14.90%)

Conference call to…

Conference call to discuss the merger with Foamix and provide a corporate update will be held on March 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
FOMX Foamix
$3.00 /

+ (+0.00%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
MNLO Menlo Therapeutics
$3.54 /

-0.62 (-14.90%)

10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
Hot Stocks
Menlo Therapeutics, Foamix announce completion of merger » 08:17
03/09/20
03/09
08:17
03/09/20
08:17
MNLO

Menlo Therapeutics

$4.16 /

+0.925 (+28.59%)

, FOMX

Foamix

$3.00 /

-0.25 (-7.69%)

Menlo Therapeutics Inc.…

Menlo Therapeutics Inc. (MNLO) announced the completion of its merger with Foamix Pharmaceuticals Ltd. (FOMX) following the satisfaction of all closing conditions required by the merger agreement. Upon completion of the merger, pursuant to the terms of the merger agreement, Foamix became a wholly owned subsidiary of Menlo. Under the terms of the merger, Foamix shareholders received 0.5924 of a share of Menlo common stock for each Foamix share owned, as well as a non-transferrable contingent stock right. These contingent stock rights potentially allow Foamix shareholders to receive additional shares of Menlo common stock based on the results of Menlo's Phase 3 trials of serlopitant for the treatment of pruritus associated with prurigo nodularis, as more fully described in the companies' joint proxy statement/prospectus on Form S-4. Foamix ordinary shares ceased trading as of the close of trading on March 6, 2020. On March 9, 2020, newly issued Menlo shares will commence trading under the ticker "MNLO" on Nasdaq. Since announcing the transaction on November 11, 2019, the Company achieved a major milestone with the launch of its first product, AMZEEQ for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older.. In the coming weeks, the Company anticipates announcing the results of its Phase 3 clinical trials of serlopitant for the treatment of pruritus associated with prurigo nodularis. Additionally, the Company expects to announce the results of its Phase 2 clinical trial for FCD105 for the treatment of acne in the second quarter of 2020. The Company has also taken meaningful steps towards facilitating a successful integration and capitalizing on expected cost synergies. Effective upon the closing of the merger, Foamix's management team will manage the Company, led by David Domzalski as CEO. As part of the transaction, Foamix has designated five of its pre-closing directors, David Domzalski, Sharon Barbari, Rex Bright, Anthony Bruno and Stanley Hirsch to serve as members of the Menlo Board of Directors. Menlo has designated two of its pre-closing directors, Steve Basta, Menlo's Chief Executive Officer prior to the consummation of the merger, and Elisabeth Sandoval, to be directors of the Company following the merger.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$4.16 /

+0.925 (+28.59%)

10/18/19 H.C. Wainwright
Menlo Therapeutics initiated with a Buy at H.C. Wainwright
FOMX Foamix
$3.00 /

-0.25 (-7.69%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.